KPV: the alpha-MSH fragment and what it is

A three-amino-acid tail of a hormone the body already makes — small, simple, and mostly studied in animal models.

TL;DR

• KPV is a three-amino-acid peptide — lysine, proline, valine — that is the tail end of alpha-MSH, a hormone the body itself produces.
• Animal research has explored its anti-inflammatory effects, especially in gut and skin models.
• FDA removed KPV from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list.

What it is

KPV is a tiny peptide. Just three amino acids: lysine, proline, valine. The name "KPV" comes from the single-letter codes for those three building blocks. It is the very end of a longer hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH (in plain English: a hormone the body uses to color skin and to dampen inflammation).

Picture alpha-MSH as a long sentence. KPV is the last three letters of that sentence. In animal studies, that short tail has retained some of the parent hormone's anti-inflammatory signal (Brzoska et al., Annals of the New York Academy of Sciences, 2003).

How it works

The simplest way to think about KPV is as a small fragment that mimics a piece of what its parent hormone does. Alpha-MSH binds to a family of receptors called melanocortin receptors. Receptors are like locks on the surface of cells. When a peptide with the right shape fits the lock, a message gets passed inside.

KPV does not bind those locks the same way alpha-MSH does. Instead, animal research suggests it works downstream — affecting inflammatory signaling inside the cell rather than docking at a melanocortin receptor on the cell surface (Dalmasso et al., Gastroenterology, 2008).

Who asks about it

People come to KPV mostly through gut-health or skin-inflammation conversations. The honest first question is some version of: what is this little three-amino-acid peptide, and is it actually well-studied?

What the research says

The published evidence is mostly in animal models — mice with chemically induced colitis, animal skin-inflammation studies, and cell-culture work. Reviews of that literature describe consistent anti-inflammatory effects in those models (Dalmasso et al., Gastroenterology, 2008). Human clinical trial data is limited. The accurate framing today is "promising in animal models; under-studied in humans."

What to know before considering it

KPV's compounding status is unsettled. Any peptide therapy requires evaluation by a licensed prescriber, and a physician's recommendation may shift as the regulatory framework changes.

The Halftime POV

KPV is a useful example of how peptide research often works: a fragment of a known molecule is studied for years in animals, hints at something interesting, and then waits for human trials to catch up. The story is unfinished. We would rather say that out loud.

---

Related reading:

• KPV peptide and inflammation research
• What are peptides? A plain-English primer
• Category 1 vs Category 2 peptides

---

FAQ

Q: What is KPV? A: KPV is a three-amino-acid peptide — lysine, proline, valine — that is the C-terminal fragment of alpha-melanocyte-stimulating hormone, a hormone the body already makes. It has been studied primarily in animal models for anti-inflammatory effects in the gut and skin.

Q: Where does KPV come from? A: KPV is the last three amino acids of alpha-MSH, a hormone the body itself produces. The compound used in research is a synthetic version of that small fragment. It is not extracted from people or animals.

Q: Is KPV available from compounding pharmacies? A: FDA removed KPV from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding KPV to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

---

Disclaimer

KPV was previously in FDA's Category 2. FDA removed it from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects. Annals of the New York Academy of Sciences, 2003.
• Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008.

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.